

In the Claims:

Claims 1-24 (Cancelled)

1 ~~26.~~ (Currently Amended): An isolated, recombinant polypeptide comprising a member selected from the group consisting of

- (a) ~~the an~~ amino acid sequence SEQ ID NO:2 ~~comprising the sequence set forth in SEQ ID NOs:2 or 4;~~
- (b) an immunogenic polypeptide ~~comprising a fragment sequence of at least 15~~ amino acids ~~contiguous of SEQ ID NO:2~~ amino acids that corresponds to an aligned contiguous segment of ~~one of~~ SEQ ID NOs:2 or 4,

wherein the immunogenic fragment isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes to a the polypeptide SEQ ID NO:2 ~~having the sequence of one of~~ SEQ ID NOs:2 or 4.

26. (Cancelled)

2 ~~27.~~ (Currently Amended): The isolated, recombinant polypeptide of claim ~~26,~~ wherein the polypeptide is according to (a).

28. (Cancelled)

3 ~~29.~~ (Currently Amended): The isolated, recombinant polypeptide of claim ~~26,~~ wherein the polypeptide is according to (b).

30. (Cancelled)

4
31. (Currently Amended): The isolated, recombinant polypeptide of claim 25, wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids; wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.

5
32. (Currently Amended): The isolated, recombinant polypeptide of claim 25 consisting of, wherein the amino acid sequence of (a) is according to SEQ ID NO:2.

Claims 33-42 (Cancelled)

6
43. (Currently Amended): An immunogenic composition comprising the isolated, recombinant polypeptide of Claim 25 and a pharmaceutically acceptable carrier.

7
44. (Previously Presented): The immunogenic composition of Claim 43, wherein the immunogenic composition comprises at least one other *Neisseria meningitidis* antigen in addition to an antigen provided by the polypeptide.

45. (Cancelled)

8
46. (Currently Amended): A method for inducing an immune response in a mammal comprising administration of the isolated, recombinant polypeptide of Claim 25.

Claims 47-49 (Cancelled)

9
50. (New): A fusion protein comprising the isolated, recombinant polypeptide of claim 25.

10 / 51. (New): An immunogenic composition comprising the isolated, recombinant polypeptide of claim ~~1~~ 2

11 / 52. (New): A fusion protein comprising the isolated, recombinant polypeptide of claim ~~2~~ 3

12 / 53. (New): An immunogenic composition comprising the isolated, recombinant polypeptide of claim ~~2~~ 3

13 / 54. (New): An immunogenic composition consisting of the amino acid sequence SEQ ID NO:2.